ClinicalTrials.gg
CompletedNCT01163734RALI-DHFUpdated Jul 12, 2012

Ranolazine in Diastolic Heart Failure

A Phase 2 interventional study of Ranolazine and Saline 0.9% and placebo tablet in Diastolic Heart Failure, sponsored by Gilead Sciences. Completed at 1 site in Germany. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2012-07-12.

Sponsored by Gilead Sciences · Phase 2 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Heart Failure, Diastolic with a site in Germany — 1 open to participants now, 2 under way, none of them phase 3. Heart Failure, Diastolic · Germany.

Enrollment
10th of 12
20 · median 61
Started
2010
the only one that year
Phase 2
2 of 15
none open now
Registered
2nd of 15
by date
Lead sponsor
1 of 15
Gilead Sciences

Among the 15 studies in Heart Failure, Diastolic with a site in Germany, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2010, is one of 2 in phase 2, and was the 2nd registered.

Heart Failure, Diastolic

199 studies on the registry are indexed under Heart Failure, Diastolic; 44 are open to participants now.

Browse Heart Failure, Diastolic studies →

Open to participants now

1 of the 15 studies in Heart Failure, Diastolic with a site in Germany is open now. Recruiting first, the newest first:

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 29 Heart Failure, Diastolic studies recruiting now, 21 (72%) set no upper age limit and 4 (14%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Heart Failure, Diastolic with a site in Germany, or all of them as a file.
02

Study summary

Patients with CAD and clinical symptoms of heart failure or patients with suspected heart failure with preserved ejection fraction (HFpEF) will be enrolled. Study drug will be given as continuous IV infusion followed by oral treatment for 13 days. LV pressures and hemodynamic data will be measured prior to and after administration of study drug. In addition, Doppler ECHO, cardiopulmonary exercise testing (CPET), and NT-pro-BNP determination will be performed. Adverse events and safety labs will be collected and monitored.

Read the detailed description

This is a randomized, double-blind, placebo-controlled proof-of-concept study of ranolazine in patients with heart failure with preserved ejection fraction (HFpEF). Patients will be randomized to receive ranolazine or placebo in a 1.5:1 ratio (12 ranolazine: 8 placebo).

Treatment will consist of intravenous infusion of study drug followed by oral treatment for a total of 14 days treatment period. Study contact will be made approximately 14 days after the treatment period to assess safety.

Cardiac catheterization will be performed for LV pressures and hemodynamic measurements before and after drug administration. Doppler ECHO, CPET, and NT-pro-BNP determination will be performed at screening and at end of study. Adverse events and safety labs will be monitored and collected.

03

Conditions studied

  • Diastolic Heart Failure

Keywords

  • Heart Failure with Preserved Ejection Fraction (HFpEF)
  • Coronary Artery Disease (CAD)
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females aged > 40 years
  2. Clinical symptoms of heart failure ( class II-III) at time of screening (e.g., dyspnea, paroxysmal nocturnal dyspnea, orthopnea, bilateral lower extremity edema)
  3. (LVEF) > 45% at screening
  4. With:

    • E/E' > 15 measured by Tissue Doppler echocardiography at screening
    • NT-pro-BNP > 220pg/mL at screening
    • Average resting LVEDP >18 mm Hg (refer to continued eligibility criteria),
    • Average resting time constant of relaxation (tau) > 50 ms at time of cardiac catheterization (refer to continued eligibility criteria)
  5. Signed

Exclusion criteria

Exclusion Criteria:

  1. Acute cardiac decompensation requiring mechanical ventilation
  2. Hypotension with blood pressure \< 90/50 mm Hg
  3. Primary hypertrophic or restrictive cardiomyopathy or systemic illness associated with infiltrative heart disease (e.g., cardiac amyloidosis)
  4. Pericardial constriction
  5. Hemodynamically significant uncorrected obstructive or regurgitant valvular disease
  6. Cor pulmonale or other causes of right heart failure not associated with left ventricular dysfunction
  7. pulmonary disease in the opinion of the Investigator or requiring home oxygen or oral therapy
  8. History of serious cardiac dysrrhythmias including atrial fibrillation with resting heart rate of > 100 beats per minute
  9. Need for treatment with Class I or III antiarrhythmic medications
  10. Implantable pacemaker, cardioverter-defibrillator, or left ventricular assist device
  11. Clinically significant chronic hepatic impairment ( Class B [moderate] or Class C [severe])
  12. Severe renal insufficiency defined as ≤30 mL/min as calculated by Cockcroft-Gault formula or Modified Diet in Renal Disease () equation.
  13. History of congenital or a family history of long syndrome, or known acquired QT interval prolongation
  14. Inability to exercise due to other co-morbidities that may affect performance of cardiopulmonary exercise test (CPET) (e.g., osteoarthritis, peripheral vascular disease)
  15. Current treatment with potent and moderate inhibitors
  16. Current treatment with potent CYP3A inducers (e.g., rifampin/rifampicin, St. John's Wort, carbamazepin/carbamazepine)
  17. Prior treatment with ranolazine
  18. Other conditions that in the opinion of the investigator may increase the risk to the patient (e.g. pts with weight ≤60 kg), prevent compliance with study protocol or compromise the quality of the clinical trial

Continued Eligibility Criteria:

Patients must continue to meet eligibility criteria and have an average (of 3 measurements) resting LVEDP > 18 mm Hg and resting tau > 50 ms at time of cardiac catheterization to receive study drug.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Ranolazine

    Drug: Ranolazine

  • Placebo comparator
    Saline 0.9%

    Saline 0.9% and placebo tablet

    Other: Saline 0.9% and placebo tablet

Interventions

  • Intravenous treatment followed oral treatment for 13 days.

    Also known as: Ranexa

  • OtherSaline 0.9% and placebo tablet

    Intravenous treatment followed by oral treatment for 13 days

    Also known as: Normal Saline

06

What researchers measure

Primary outcomes

  1. Change from baseline to 30 minutes in cardiac catheterization hemodynamic parameters at both resting and paced conditions

    Change from baseline to 30 minutes from initiation of study drug bolus No.1 in cardiac catheterization hemodynamic parameters at both resting and paced conditions: Time-constant of relaxation (tau) Left ventricular end-diastolic pressure (LVEDP) dP/dtmin (minimal rate of LV pressure change)

    Time frame: Baseline to 30 minutes

Secondary outcomes

  1. Change from baseline to Day 14 in mitral E wave velocity/mitral annular velocity (E/E') ratio

    Time frame: Baseline to Day 14

  2. Change from baseline to Day 14 in VO2 max

    Time frame: Baseline to Day 14

  3. Change from baseline to Day 14 in N-terminal pro-brain B-type natriuretic peptide (NT-pro-BNP)

    Time frame: Baseline to Day 14

07

Study locations

1 site
  • University Medicine Goettingen (UMG)
    Goettingen, Germany
08

References and documents

Publications

  • Maier LS, Layug B, Karwatowska-Prokopczuk E, Belardinelli L, Lee S, Sander J, Lang C, Wachter R, Edelmann F, Hasenfuss G, Jacobshagen C. RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study. JACC Heart Fail. 2013 Apr;1(2):115-22. doi: 10.1016/j.jchf.2012.12.002. Epub 2013 Apr 1. PubMed 24621836 ↗
  • Jacobshagen C, Belardinelli L, Hasenfuss G, Maier LS. Ranolazine for the treatment of heart failure with preserved ejection fraction: background, aims, and design of the RALI-DHF study. Clin Cardiol. 2011 Jul;34(7):426-32. doi: 10.1002/clc.20897. Epub 2011 Apr 27. PubMed 21538388 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2010, a primary completion of Feb 2011 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2010
First posted
Jul 16, 2010
Start
Apr 2010
Primary completionActual
Feb 2011
CompletionActual
Feb 2011
Last update
Jul 12, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01163734
Lead sponsor
Gilead Sciences
Collaborators
University Medicine Göttingen, Cardiac Center
Responsible party
Sponsor
First posted
Jul 16, 2010
Start date
Apr 2010
Primary completion
Feb 2011
Completion
Feb 2011
Last update
Jul 12, 2012

Study contacts

Lars S. Maier, MD
principal investigator · University Medicine Göttingen, Cardiac Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranolazine

Start the discussion